Castration-resistant Clinical Trials in Baltimore, Maryland
18 recruitingBaltimore, Maryland
Showing 1–18 of 18 trials
Recruiting
Phase 3
A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
Metastatic Castration-resistant Prostate Cancer
Amgen750 enrolled134 locationsNCT07213674
Recruiting
Phase 1Phase 2
A Phase 1b/2a Study of Pocenbrodib as Monotherapy and in Combination With Darolutamide in Participants With mCRPC
Prostate CancermCRPC (Metastatic Castration-resistant Prostate Cancer)
Pathos AI, Inc.120 enrolled18 locationsNCT06785636
Recruiting
Phase 3
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
Metastatic Castration-resistant Prostate Cancer (mCRPC)Prostatic Neoplasms
Merck Sharp & Dohme LLC1,314 enrolled329 locationsNCT06136650
Recruiting
Phase 3
A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer
Prostatic Neoplasms, Castration-Resistant
Janssen Research & Development, LLC800 enrolled136 locationsNCT07225946
Recruiting
Phase 3
A Study of Pasritamig Versus Placebo in Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)
Metastatic Castration-resistant Prostate Neoplasms
Janssen Research & Development, LLC663 enrolled168 locationsNCT07164443
Recruiting
Phase 1Phase 2
FOG-001 in Locally Advanced or Metastatic Solid Tumors
Colorectal, CancerProstate CancerCancer+12 more
Parabilis Medicines, Inc.595 enrolled33 locationsNCT05919264
Recruiting
Phase 1
Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors
Head and Neck Squamous Cell Carcinoma (HNSCC)Non-small Cell Lung Cancer (NSCLC)Solid Tumor+7 more
Exelixis1,314 enrolled122 locationsNCT05176483
Recruiting
Phase 1Phase 2
Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A)
Prostatic Neoplasms, Castration-Resistant
Merck Sharp & Dohme LLC220 enrolled77 locationsNCT06353386
Recruiting
Phase 3
A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer
Metastatic Castration-resistant Prostate Cancer
Celgene960 enrolled282 locationsNCT06764485
Recruiting
Phase 1Phase 2
A Trial to Find Out if REGN4336 is Safe and How Well it Works Alone and in Combination With REGN5678 for Adult Participants With Advanced Prostate Cancer
Metastatic Castration-resistant Prostate Cancer
Regeneron Pharmaceuticals228 enrolled14 locationsNCT05125016
Recruiting
Phase 1
Phase 1 Study of ACE-232 to Treat Patients With Metastatic Castration-Resistant Prostate Cancer
Prostate Cancer (Adenocarcinoma)mCRPC (Metastatic Castration-resistant Prostate Cancer)
Acerand Therapeutics (Hong Kong) Limited67 enrolled8 locationsNCT06801236
Recruiting
Phase 2
Supraphysiologic Testosterone Priming Induces Darolutamide Extended Response
Metastatic Castration-resistant Prostate Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins60 enrolled1 locationNCT07142551
Recruiting
Impact of DNA Repair Pathway Alterations on Sensitivity to Radium-223 in Bone Metastatic Castration-resistant Prostate Cancer
Castration-Resistant Prostate CarcinomaMetastatic Prostate CarcinomaStage IVB Prostate Cancer AJCC v8+1 more
University of Washington48 enrolled4 locationsNCT04489719
Recruiting
Phase 2
Bipolar Androgen Therapy (BAT) and Radium-223 (RAD) in Metastatic Castration-resistant Prostate Cancer (mCRPC)
Metastatic Prostate AdenocarcinomaProstate AdenocarcinomaCastration-resistant
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins47 enrolled2 locationsNCT04704505
Recruiting
Phase 1
Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)
Prostate CancerMetastatic Castration-resistant Prostate CancerCastration-Resistant Prostatic Cancer
Janux Therapeutics272 enrolled35 locationsNCT05519449
Recruiting
Phase 2
The COSMYC Trial (COmbined Suppression of MYC)
Metastatic Castration-resistant Prostate Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins50 enrolled1 locationNCT06922318
Recruiting
Phase 1Phase 2
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
Endometrial CancerAdvanced Solid TumorDiffuse Large B Cell Lymphoma+5 more
Novartis Pharmaceuticals275 enrolled60 locationsNCT04104776
Recruiting
Phase 1Phase 2
[Lu-177]Ludotadipep in Castration-resistant Prostate Cancer(CRPC): Investigation of Drug and Application
Metastatic Castration-resistant Prostate Cancer
FutureChem26 enrolled4 locationsNCT05458544